ArticlePloS one2026
Serum proteomic changes in atopic dermatitis patients treated with cyclosporine.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peripheral Immune Modulation in Atopic Dermatitis During Dupilumab or Baricitinib Treatment Is Limited, as Assessed by Proteomic, Transcriptomic, and Torque Teno Virus Analyses.International journal of molecular sciences · 2026Article
- Correction: Serum proteomic changes in atopic dermatitis patients treated with cyclosporine.PloS one · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite significant advancements in atopic dermatitis (AD) treatment, the underlying pathogenesis remains unclear. Understanding flare and remission mechanisms is essential for understanding disease course, evaluating treatment and developing therapeutic strategies. Although biomarkers show promise for assessing disease severity, their identification, validation and clinical utility demand further research.
objectivesTo investigate inflammatory changes involved in AD flares and remissions, we studied changes in expression of 368 circulating biomarkers during cyclosporine (CsA) treatment.
methodsThe study included 40 AD patients experiencing a disease flare and starting CsA treatment. Serum samples were collected at baseline, after 2 and 4 weeks of treatment.
resultsCsA treatment induced a rapid improvement of disease severity and reduced proteins related to Th2, Th1 and Th17 pathways. Four novel markers, FKBP1B, PDLIM7, MAP2K6 and EIF4G1 demonstrated decreased expression levels after treatment. In addition, CCL17/TARC and OX40 levels showed a strong correlation with disease severity. Interestingly, NME3, SMOC2, and GAL showed increased expression after treatment. We identified four biomarkers that may be linked to the pathogenesis of flares and remissions. Lastly, we identified OX40 as a potential biomarker for disease severity.
conclusionWe identified four novel serum biomarkers possibly related to treatment effect and we identified OX40 as a potential serum biomarker for assessing disease severity. These findings enhance understanding of AD pathogenesis and offer tools for monitoring therapeutic response and disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.